Obesity is associated with greater treatment requirements in ulcerative colitis: a propensity score-matched real-world study
Background Obesity is increasingly common among patients with ulcerative colitis (UC), but its specific association with disease outcomes remains unclear. We evaluated whether body mass index (BMI) categories were associated with treatment burden, disease extent, healthcare utilization, and colectomy risk in patients with UC. Methods We performed a retrospective cohort study using the TriNetX Global Collaborative Network. Adult patients with UC and a BMI recorded within 6 months before or after diagnosis were classified as normal weight (18.0–24.9 kg/m 2 ), overweight (25.0–29.9 kg/m 2 ), or obesity (≥30.0 kg/m 2 ). Patients with a BMI below 18.0 kg/m 2 were excluded. Separate 1:1 propensity score-matched comparisons were performed between BMI groups. Primary outcomes were systemic corticosteroid exposure and initiation of advanced therapies. Secondary outcomes included documented extensive colitis, hospitalization, and colectomy. Results Among 109,044 patients with UC (36,637 normal weight, 35,047 overweight, and 37,360 with obesity), obesity was associated with higher systemic corticosteroid exposure (45.0% vs. 40.8%; risk ratio 1.10, 95% confidence interval 1.07–1.13) and more frequent initiation of advanced therapies (8.6% vs. 7.2%; risk ratio 1.19, 95% confidence interval 1.12–1.26). Obesity was also associated with earlier initiation of advanced therapies (hazard ratio 1.13, 95% confidence interval 1.06–1.20; log-rank p < 0.0001) and more frequent documentation of extensive colitis (18.8% vs. 17.2%; risk ratio 1.09, 95% confidence interval 1.06–1.13). Hospitalization was slightly less frequent among patients with obesity (14.7% vs. 15.5%; risk ratio 0.94, 95% confidence interval 0.91–0.98), whereas colectomy risk did not differ significantly. Outcomes among patients with overweight were generally similar to those of normal-weight individuals. Discussion Obesity was associated with greater treatment requirements and more frequent documentation of extensive colitis in patients with UC. These findings support an association between obesity and increased therapeutic burden in routine clinical practice and warrant further investigation of metabolic and immunometabolic factors in UC.
Authors
- Sara Massironi (ORCID: https://orcid.org/0000-0003-3214-8192)
- Virginia Solitano (ORCID: https://orcid.org/0000-0002-2935-6778)
- Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
- Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
- Mariangela Allocca (ORCID: https://orcid.org/0000-0002-7204-1739)
- Vipul Jairath (ORCID: https://orcid.org/0000-0003-1590-0338)
- Federica Furfaro (ORCID: https://orcid.org/0000-0002-4308-7295)
Institutions
- Western University (CA)
- Vita-Salute San Raffaele University (IT)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- IRCCS Ospedale San Raffaele (IT)
- Université de Lorraine (FR)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fmed.2026.1941666
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00